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Abstract
Amajor challenge in cancer biology is to monitor and understand cancer metabolism in vivowith the goal of improved
diagnosis and perhaps therapy. Because of the complexity of biochemical pathways, tracer methods are required for
detecting specific enzyme-catalyzed reactions. Stable isotopes such as 13C or 15N with detection by nuclear magnetic
resonance provide the necessary information about tissue biochemistry, but the crucial metabolites are present in
low concentration and therefore are beyond the detection threshold of traditional magnetic resonance methods. A
solution is to improve sensitivity by a factor of 10,000 or more by temporarily redistributing the populations of nuclear
spins in a magnetic field, a process termed hyperpolarization. Although this effect is short-lived, hyperpolarized mole-
cules can be generated in an aqueous solution and infused in vivo where metabolism generates products that can be
imaged. This discovery lifts the primary constraint on magnetic resonance imaging for monitoring metabolism—poor
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sensitivity—while preserving the advantage of biochemical information. The purpose of this report was to briefly
summarize the known abnormalities in cancer metabolism, the value and limitations of current imaging methods
for metabolism, and the principles of hyperpolarization. Recent preclinical applications are described. Hyperpolari-
zation technology is still in its infancy, and current polarizer equipment and methods are suboptimal. Nevertheless,
there are no fundamental barriers to rapid translation of this exciting technology to clinical research and perhaps
clinical care.
Neoplasia (2011) 13, 81–97
Introduction
Our understanding of cancer biology and our ability to image ma-
lignancies have evolved radically in the past 40 years. Each major
step forward in cancer imaging was achieved by advances across mul-
tiple fields including physics, chemistry, medicine, and computa-
tion. Despite these successes, cancer imaging still lacks reliability in
providing key biologic information about the tumor—its genetics,
clinical stage, rate of growth, response to therapy, and others—
underscoring the continued need for novel approaches. Recently,
dramatic improvements in our ability to image specific molecules
have been demonstrated using magnetic resonance imaging (MRI)
of molecules prepared by a process termed hyperpolarization. Imaging
hyperpolarized nuclei again presents the fields of oncology and med-
ical imaging with an opportunity to dramatically improve our ability
to identify and understand tumor tissue. In addition to the absence
of ionizing radiation and convenient integration with standard MRI,
imaging hyperpolarized nuclei offers the prospect of monitoring tu-
mor metabolism essentially noninvasively. Imaging of hyperpolarized
13C-labeled substrates has attracted particular interest because, unlike
any other imaging technology, the products of metabolism in a specific
enzyme-catalyzed reaction may be observed based on inherent MR fre-
quency differences.
In this report, we provide a brief survey of our understanding of
cancer metabolism, the current role of positron tomography and mag-
netic resonance spectroscopy (MRS) to detect metabolism in cancer,
a basic review of the physics of hyperpolarization, and a summary of
recent applications in biology. Although many of the important re-
cent advances are technical, those have been de-emphasized. Imaging
hyperpolarized inert molecules such as those used for vascular imag-
ing is also not discussed. Instead, we focus on tumor metabolism and
the use of hyperpolarization methods to monitor dynamic metabolic
processes in vivo. It should also be emphasized that other diseases—
diabetes, ischemic heart disease, diffuse hepatocellular diseases, stroke,
to name a few—are also associated with marked metabolic abnor-
malities and that new methods to probe tissue biochemistry should
be equally valuable. The academic and industrial communities have
an unusual opportunity and perhaps a responsibility to move this
technology forward quickly because there is a strong clinical need to
acquire quantitative information about metabolism in primary and
metastatic lesions to enhance cancer care. Although it is true that hy-
perpolarized MR is technically challenging, the underlying MRI tech-
niques and necessary engineering knowledge are currently available.
Furthermore, the chemical principles and knowledge of biochemical
pathways required to interpret the images are also well known. There
are no known insurmountable barriers in developing this technology
for human studies, and a future role in assessment of cancer patients
can be envisioned.
Metabolism in Cancer
Cancer metabolism can be viewed as the sum of a large but finite
number of interdependent biochemical pathways, each of which pro-
vides a specific function for the cell [1,2]. Many of these pathways,
particularly glycolysis, the pentose phosphate pathway, the tricarbox-
ylic acid (TCA) cycle, oxidative phosphorylation, and the synthesis of
nucleotides and lipids, either are required to support the intense bio-
synthetic demands of cell proliferation or are subject to alternative
regulation in cancer. Below, we outline six concepts that illustrate
the important links between tumor biology and metabolism.
Historically, the first important concept was that tumor metabolism
differs from that of the surrounding tissue. In the 1920s, Otto Warburg
demonstrated that tumors had high rates of glucose consumption and
lactate production compared with the normal tissue [3,4]. This seminal
observation created the field of tumor metabolism, which has been
dominated largely by the study of glycolysis ever since [5]. Enhanced
fluxes in other pathways including lipid synthesis, amino acid transport,
and nucleotide transport have also been observed in aggressive tumors
and are being investigated for diagnostic purposes [6] or as therapeutic
targets [7–9].
Regulation of tissue pH is also abnormal in cancer. Most tumors have
an acidic extracellular pH compared with normal tissue, and this can be
correlated with prognosis and response to treatment [10–12]. Secondary
changes in malignant tissue such as inflammation and ischemia are
among the pathologic states associated with an altered acid-base balance
[13–16]. Despite the importance of pH and its relationship to the
disease, there is currently no clinical tool available to image the spatial
distribution of pH in humans.
More recently, it has been shown that tumor suppressors and onco-
genes regulate nutrient uptake and metabolic flux. Thus, tumor me-
tabolism is linked mechanistically to the mutations that cause cancer.
As early as the 1980s, it was determined that overexpressing the onco-
genes ras or src in fibroblasts was sufficient to drive glucose uptake
[17], and numerous subsequent studies have documented the me-
tabolic effects of various mutations or aberrant signaling activities.
Many of these studies have focused on glucose uptake, but others sug-
gest wider influence involving either the specific fates of glucose carbon
within the cell or the ability to orchestrate multiple pathways simulta-
neously. For example, the oncogenic transcription factor c-Myc seems
to regulate cellular handling of both glucose and glutamine, which, to-
gether, feed the metabolic pathways required for cell growth and
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proliferation [18–20]. Deletion of the tumor suppressor gene TP53
can stimulate glucose uptake and suppress the oxidation of pyruvate,
both of which are hallmarks of the metabolic phenotype described
by Warburg [16,21]. Together, these observations support the notion
that alterations in metabolism are common downstream indicators of
the transformed state.
A fourth and perhaps surprising principle is that mutations in met-
abolic enzymes may cause a small number of cancers. Pheochromo-
cytoma and paraganglioma can be caused by mutations in subunits of
succinate dehydrogenase, an enzyme complex that [16,21] functions
in both the TCA cycle and electron transport [13,22,23]. Similarly,
mutations in the TCA cycle enzyme fumarate hydratase occur in a
familial form of leiomyomatosis and renal cell cancer [13,22,23]. In
both of these diseases, affected patients inherit one mutant allele and
their tumors exhibit loss of the other, resulting in a severe deficiency
of enzyme activity in the tumor. The mechanism for tumorigenesis in
these diseases is unknown but may be mediated by accumulations of
succinate and fumarate, both of which have been demonstrated to
elicit effects normally brought on by hypoxia [24]. More recently,
mutations in the two isoforms of isocitrate dehydrogenase, IDH1
and IDH2, were identified in glioblastoma, low-grade gliomas, and
acute myelogenous leukemia [25–27]. Although the mutant enzymes
lack the canonical IDH enzymatic activity, the genetics of these tumors
pointed to a more complex mechanism of tumorigenesis than simple
loss of function. In particular, the fact that these somatically acquired
mutations were confined to a single codon and were not accompanied
by loss of heterozygosity suggested that the mutant alleles functioned as
oncogenes. Consistent with this idea, mutant IDH1 proteins were re-
cently shown to possess a new enzymatic activity, the production of the
metabolite 2-hydroxyglutaric acid from alpha-KG [28]. It should be
noted that several other inborn errors of metabolism, including glycogen
storage disease type 1 and tyrosinemia type 1, are also associated with
cancer. These findings together indicate that the detection of abnormal
metabolic fluxes or the accumulation of unusual metabolites could be
used to monitor the predisposition to cancer in humans.
Some aspects of metabolismmay predict disease severity or outcomes
in cancer. For example, the enzyme transketolase-like 1 (TKTL1),
which catalyzes transfer reactions between glycolysis and the nonoxida-
tive branch of the pentose phosphate pathway, is overexpressed in a
number of tumor types. A large study involving more than 1000 pri-
mary tumor samples determined that a high expression of TKTL1 pre-
dicted early mortality in colon and urothelial cancers [29]. Another
study demonstrated a similar connection between TKTL1 expression
and distant metastases in ovarian carcinoma [30]. These observations
raise the appealing possibility that methods to monitor the activity of
TKTL1, fatty acid synthase (FAS), and other enzymes in vivo would
provide novel biomarkers of disease severity, enabling clinicians to tailor
treatment regimens.
Finally, clinical oncologists have long known that tumor growth
can be suppressed by modifying metabolic activity in some instances.
For example, L-asparaginase, an important component of treatment
regimens in pediatric leukemias, operates on the principle that the
demand for asparagine in rapidly proliferating tumor cells exceeds
what can be supplied through endogenous de novo asparagine synthe-
sis. Infusion of L-asparaginase reduces the availability of asparagine
from the blood supply, thereby specifically limiting the growth of
the tumor cells. Antimetabolite therapies such as methotrexate sup-
press de novo nucleotide synthesis in proliferating cells. More recent
studies have demonstrated that genetic or pharmacological manip-
ulations of other metabolic activities are effective in limiting the
growth of xenografts [31–34]. These studies have generated excite-
ment about developing related approaches in human cancer.
Role of Molecular Imaging in Clinical Oncology
Tissue biopsy and histopathology at a single point in time is the stan-
dard approach to diagnose cancer. Once a diagnosis is established,
therapeutic decisions and follow-up typically rely on a combination
of clinical evaluation and radiologic imaging. Of course, methods
that require invasive tissue sampling are undesirable in many re-
spects, particularly for longitudinal monitoring, screening programs,
and efforts to understand factors influencing cancer risk. For these
reasons, there is intense interest in minimally invasive technologies
that provide specific diagnoses, information about the disease stage,
and prediction and/or assessment of response to therapy.
Molecular imaging may be defined as “the visualization, character-
ization, and measurement of biologic processes at the molecular and
cellular levels” [35]. In principle, molecular imaging methods can
detect specific biologic processes that are changed in cancer relative
to surrounding normal tissue. The power of molecular imaging lies
in the fact that it is essentially noninvasive and thus can be used to
probe the whole tumor volume repeatedly over time. Imaging can
not only support an initial diagnosis but also monitor progress in
terms of staging, restaging, treatment response, and identification of
recurrence, both at the primary tumor and at distant metastatic sites.
For the purposes of this report, we consider “metabolic imaging” as a
subset of molecular imaging methods that provide more-or-less direct
information about tissue metabolism. Many research methods are
sensitive to tissue metabolism, but we limit our comments to two
metabolic imaging methods that are widely used in clinical practice
or clinical research: positron tomography and MRS.
Positron Emission Tomography
Positron emission tomography (PET) images the uptake of an in-
jected radiolabeled molecule in the tumor and, when combined with
x-ray computed tomography (CT), provides both molecular informa-
tion and anatomic localization. The amount of radiolabeled material
that is injected is negligible compared with the normal concentration
of metabolites, and consequently, PET tracers do not disrupt tissue
physiology. The most commonly used PET tracer is [18F]-fluoro-2-
deoxyglucose (FDG), which exploits the high glycolytic rate of many
tumors. Because of high levels of glucose transporters and hexokinase
activity, cancer cells demonstrate high FDG uptake and phosphory-
lation compared with the normal tissue. Phosphorylated FDG cannot
be metabolized further and becomes “trapped” inside the tumor, and
over time, regions of high FDG accumulation can be easily distin-
guished. The diagnostic power of FDG-PET lies in its ability to stage
disease, monitor treatment response, and detect recurrence, rather
than in initial diagnosis [36].
Many other clinically relevant features of tumor metabolism can be
probed with current PET technology. For example, choline, which is
transported into cells and incorporated into phospholipids, can be
labeled with either [11C] or [18F] and has found application primarily
in prostate cancer [37,38], hepatocellular carcinoma [39], and lung
and brain lesions [40]. Cell division has been monitored with the
thymidine analog, 3′-deoxy-3′-[18F]fluorothymidine. It is trapped
in cells after phosphorylation by thymidine kinase 1, which is especially
active during the S phase of the cell cycle, and thus has been used to
detect dividing cells in vivo. The diagnostic power of 3′-deoxy-3′-[18F]
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fluorothymidine is in distinguishing malignant from benign lesions, in
assessing response to therapy, and in grading lung, breast, and colorectal
cancers and lymphoma [41].
Other avenues of investigation in PET-based molecular imaging of
cancer include the use of the somatostatin analog 68Ga-DOTATOC,
which binds to somatostatin receptor 2 with high affinity and has been
used to diagnose neuroendocrine tumors [42]. Estrogen receptor (ER)
expression can be imaged using 16-α-[18F] fluoro-17-β-estradiol,
which binds to both subtypes ERα and ERβ. Arginine-glycine-aspartic
acid–containing peptide ligands, which bind to the αvβ3 integrin that is
upregulated on angiogenic blood vessels, have shown promise for im-
aging tumor angiogenesis and assessing the effects of antiangiogenic
drugs [43]. Hypoxia, resulting from an imbalance between perfusion
and metabolism, can be imaged by exploiting the reduction and bind-
ing of nitroimidazoles under hypoxic conditions [44].
These and other PET agents have been used extensively in clinical
oncology research, and their practical value in the clinic has been
demonstrated. However, the value of these techniques for determin-
ing the fate of a tracer in alternative metabolic pathways is limited by
the absence of chemical information in PET images. Inevitably, there
are also concerns related to radiation dose with PET/CT and the
practicalities of radiation containment in the clinic.
MRI and MRS
1H MRS can easily be incorporated into existing MRI examina-
tions [45–47] using currently available clinical MR scanners. For
these reasons, there has long been interest in evaluating endogenous
tumor metabolites by 1H MRS owing to its relatively high sensitivity
and nearly 100% natural abundance.
1H signals from choline-containing molecules are frequently elevated
in cancer, and this has been correlated with cellular proliferation in
brain, prostate, breast [46,48,49], colon, and cervical cancers [50].
Choline abundance can be used to predict the tumor’s histologic grade
with low false-positive and false-negative rates. For example, many
breast tumors show high concentrations of total choline [51,52],
whereas benign lesions are generally contain low concentrations of
choline [53]. Moreover, spatial mapping of choline signals can reveal
aggressive tumor regions and their response to therapy [50]. Because
brain tumors exhibit elevated choline and decreased N-acetyl aspartate
concentrations, the Cho/N-acetyl aspartate ratio has been widely used
as a prognostic marker to distinguish low- and high-grade disease in
astrocytomas [54,55] and gliomas [56]. Monitoring the increase in this
ratio may also be useful for detecting progression [56]. Other metab-
olite ratios, such as choline/creatine, can differentiate low-grade gli-
oma from benign demyelinating disease [57] and high- from low-grade
oligodendroglial tumors [58]. Prostate 1H spectra exhibit elevated cho-
line and reduced citrate in regions of prostate cancer [46].
The relatively poor spatial resolution in MRS imaging (MRSI),
typically resulting in voxels of 0.16 to 1 cm3 [46,49,59,60], is a lim-
iting factor. Nonetheless, if validated in large-scale trials, MRS could
improve clinical characterization of brain lesions and potentially
avoid difficult biopsies. Breast MRS could be a valuable adjunct to
MRI for lesion grading and monitoring of treatment response, par-
ticularly for improving specificity. Prostate cancer localization and
grading through three-dimensional MRSI could be used to select
patient groups in which biopsy is not necessary, saving patients un-
necessary invasive procedures and anxiety. MR, of course, offers the
opportunity to detect drugs and other metabolism by 19F [61,62],
31P [63,64], and 13C [65], but these research applications are not
widespread. In the future, large-scale, multisite, prospective trials are
needed to confirm the very promising results of 1HMRS achieved thus
far to assess clinical value.
Current Limitations of Molecular Imaging
Many clinically relevant aspects of tumor cell biology are reflected
in metabolic activity. Moreover, the complexity of intermediary me-
tabolism also provides a host of potential targets to image. Unfortu-
nately, current modalities provide only snapshots of metabolism and
are blind to many of the subtleties that reflect the tumor’s biologic
state. For example, despite FDG-PET’s success in detecting tumors
[5], not all tumors consume glucose avidly enough to give a positive
FDG-PET signal. A “cold” tumor could be metabolically inactive, or
it might use alternative substrates to support survival and to fuel
growth. A more vexing problem is that even a positive result on
FDG-PET is open to multiple interpretations because FDG-PET
provides no information about glucose metabolism beyond import
and phosphorylation. Carbon from glucose can supply glycolysis, the
pentose phosphate pathway, oxidative metabolism in the mitochondria,
and biosynthetic reactions, each of which serves different functions
within the cell. The allocation of carbon from glucose and other nutri-
ents into these pathways is determined by a combination of extrinsic
and intrinsic modifiers of metabolism and ultimately determines
whether tumor cells die or survive and whether they remain quiescent
or undergo growth and proliferation [1]. For example, glucose uptake is
stimulated by the activation of oncogenic signaling [17,66] or by hyp-
oxia, which suppresses the entry of glucose carbon into oxidative path-
ways and inhibits proliferation [67]. Thus, it is impossible based on
FDG-PET alone to know whether a tumor is growing actively.
1H MRS is attractive but with most clinical systems, only a limited
number of metabolites are present at concentrations that allow useful
spatial mapping. This significantly limits the level of analysis possible
for a tumor. The information is in some ways more useful than PET
in that multiple metabolites can be spatially resolved in a single im-
aging protocol. However, only static concentrations are detected,
rather than tracer uptake, which is one of the most useful features
of FDG-PET.
What Is Hyperpolarization?
It is convenient to think of MR as a process to detect alignment of
magnetic nuclei with or against an applied magnetic field. The term
polarization refers to the difference in the fraction of nuclei in these
two energy states. Under normal conditions, the degree of nuclear
spin polarization is proportional to the gamma (γ) and B0/T, where
γ is the nucleus-specific gyromagnetic ratio constant, B0 is the ap-
plied magnetic field, and T is the temperature in Kelvin. The MR
signal is proportional to the spin polarization that is typically on the
order of 0.0001% to 0.0005% depending on the nucleus and field.
This very low level of polarization results in one of the main draw-
backs of all MR methods, namely, limited signal. In fact, clinical
MRI is so successful only because the high concentration of protons
in water and fat overcomes poor polarization. Efforts to improve sig-
nal by increasing the applied field B0 are feasible but limited to only a
few folds by practical constraints and cost.
In the context of MR, the term hyperpolarization refers to a pro-
cedure that drives nuclei, temporarily, into a significant redistribution
of the ordinary population of energy levels. This artificially created
nonequilibrium condition of the nuclei in a magnetic field can be
accomplished using various techniques as described in recent review
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articles and book chapters [65,68–71]. On hyperpolarization, the sig-
nal from a given number of nuclear spins can be raised by a factor of
10,000 or more when compared with equilibrium conditions in clini-
cally available MRI scanners. This staggering increase in signal has the
potential to substantially overcome one of the key limitations of MR:
limited sensitivity.
Multiple methods, outlined below, have been described to generate
the hyperpolarized state. Regardless of method, the hyperpolarized
spin states are not stable in the sense that the induced massive spin
polarization decays during a relatively short period to an equilibrium
value. The rate of this exponential decay process is governed by spin-
lattice relaxation with a time constant T 1. A slow relaxation rate
corresponds to a long T 1. Because the ultimate goal of using hyper-
polarization in biomedicine is to image metabolic events in real time,
hyperpolarized states with sufficiently long lifetimes (>20 seconds) are
required. Long T 1’s are typical for relatively low-γ nuclei such as
13C.
The relaxation rates are generally longer than those of protons. Car-
bon nuclei that are not directly bonded to protons such as carboxyl
carbons or quaternary carbons have T 1’s ranging up to 80 seconds
depending on the molecule and the magnitude of B0.
The first and still the only hyperpolarization method that has been
used to generate polarized materials for human studies is optical
pumping of 3He or spin-exchange optical pumping of 3He and
129Xe [72–76]. Two other hyperpolarization techniques have been
developed for applications to MRS and MRI: parahydrogen-induced
polarization (PHIP) [77,78] and dynamic nuclear polarization
(DNP) [79,80]. Both methods can be used to polarize molecules
containing 13C, an important advance because of the very large
chemical shift range of 13C in organic molecules and the opportunity
for direct tracing of drugs or key metabolic intermediates.
Parahydrogen-Induced Polarization
PHIP methods exploit the spin order of the parahydrogen singlet
state—the source of hyperpolarization. Although they can be imple-
mented in a number of ways to use the spin order of parahydrogen
singlet, the parahydrogen and synthesis allow dramatically enhanced
nuclear alignment (PASADENA) effect is most widely used to pre-
pare hyperpolarized tracer compounds [77,78,81]. PASADENA is
unique in its ability to achieve hyperpolarization in aqueous medium
in seconds, using cis addition of parahydrogen (pH2) across alkene or
alkyne bonds followed by the spin order transfer from nascent pro-
tons to 13C or 15N with a theoretical polarization limit of 100%.
PASADENA is also inexpensive, portable, and easy to maintain, as
the hyperpolarization can be conducted in a low-field magnet of only
a few millitesla [82]. Rh-based molecular catalysts allow molecular
hydrogenation of the unsaturated bond and spin order transfer from
parahydrogen spins on the time scale of several seconds [82]. The
toxicity of the catalyst remains a concern for extending PHIP to
clinical applications.
The spin order transfer sequence used in PASADENA relies on the
spin-spin couplings between the parahydrogen and the 13C or 15N
nuclei of the labeled substrate. Deuteration of the hyperpolarized
substrate is desirable in simplifying the spin system and in increasing
the lifetime of the hyperpolarized substrate [83]. The development of
metabolic imaging applications using the PASADENA technique is
hampered by the requirement to have a precursor molecule that can
be hydrogenated. This limits the choice of target molecules for imag-
ing. Recently, an alternative PHIP method has been proposed under
the acronym SABRE (signal amplification by reversible exchange)
[84,85] in which the polarization transfer step does not require a
hydrogenation reaction. Instead, the parahydrogen and target mole-
cules are brought together temporarily on a suitable template, and
the polarization is transferred in a low magnetic field from the hydro-
gen nuclei in the parahydrogen to scalar coupled nuclei (hydrogen and
X-nuclei) in the target molecule. The polarization transfer process can
generate Z -magnetization but also multiple spin coherences [86] and
is therefore particularly suited for the generation of long-lived states
[87–90]. Retaining the advantages of hydrogenative PHIP, this new
method may allow the polarization of additional molecules.
Dynamic Nuclear Polarization
DNP is based on the transfer of polarization from the electron
spins of paramagnetic centers embedded in a glassy frozen solution
to neighboring nuclear spins through dipolar interactions [79,80].
Because the magnetogyric ratio of an electron is so high compared
with that for any nucleus, at any applied field, unpaired electrons will
be more polarized; the goal is to transfer this polarization to informa-
tive nuclei. For the technique to be efficient, the paramagnetic cen-
ters, usually stable radicals, have to be homogeneously distributed in
the frozen solution containing the molecules of interest. The optimal
temperature for an efficient polarization transfer is about 1 K. DNP
methods were developed initially for applications in nuclear and par-
ticle physics research, but they became of interest for biomedical ap-
plications after the introduction of the dissolution method by
Ardenkjaer-Larsen et al. in 2003 [80]. The dissolution step rapidly
transforms the frozen solution into a dilute room temperature solu-
tion in which the nuclear spins of the molecules of interest remain
polarized. The molecules are then considered to be hyperpolarized.
Dissolution DNP yields 13C nuclear polarization in liquids up to
about 40% in selected molecules [80]. The technique is quite versa-
tile and has been used to hyperpolarize 1H, 6Li, 13C, 15N, and 89Y in
a variety of molecules or nanoparticles [56,69,91–97].
The crucial ingredients for efficiently hyperpolarizing molecules
through DNP are the following: 1) Efficient paramagnetic centers
(stable free radicals); trityl radicals have been the most commonly
used free radicals to date. 2) Adapted cryogenic equipment to keep
the frozen solution at around 1 K during the microwave irradiation
driving the polarization transfer; two designs have been implemented
so far: a system with a variable temperature insert that is placed in the
helium bath used to maintain the polarizer superconducting magnet
at 4.2 K [96] and a system with a separate cryostat that can be in-
serted in a standard room temperature bore superconducting magnet
[98]. In addition, although the original field used in dissolution
DNP was 3.35 T, it has recently been shown that greater polarization
can be obtained at higher fields, about 4.6 to 5.0 T [99,100]. 3) An
efficient means is needed to dissolve the frozen solution and rapidly
transfer it to the MR equipment with minimal loss of the hyper-
polarized state; a specific device minimizing the delay between the
dissolution and the infusion of DNP-enhanced molecules has been
implemented for in vivo applications [98].
The applicability of this technique to investigating metabolic path-
ways requires that the 13C or 15N labeled substrate is a water-soluble,
endogenous or exogenous metabolite with a long T 1 relaxation time
in the liquid state. A limitation that still has to be overcome is the
relatively long period required to prepare the hyperpolarized nuclei,
typically 30 to 90 minutes, when using DNP. The strength of DNP
is that, in principle, virtually any biomolecule can be hyperpolarized.
However, in practice, the ability to capitalize on the potential of new
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hyperpolarized probes requires knowledge of whether the probe
polarizes sufficiently, which is an interplay between spin diffusion,
polarization transfer, and relaxation.
Nuclei for Hyperpolarization and the Role of Relaxation
As we have seen, multiple methods can induce a hyperpolarized
state. However, once the hyperpolarized compound is delivered in vivo,
the hyperpolarized state decreases to its equilibrium value with a time
constant according to the spin lattice relaxation time T 1. As a result of
both metabolism and this relaxation process, the resulting MR signal
can be significantly reduced when detected in vivo. Consequently, a
critical challenge in translation of this technology is development of
probes that balance three features. First, the T 1 must be sufficiently
long so that a significant fraction of the hyperpolarized state is preserved
in vivo. Second, the metabolic pathway or process must be sufficiently
rapid that, given the T 1 of the polarized molecule, useful information
can be obtained. Third, the process or pathway must be relevant to
tumor biology.
These factors are also relevant, of course, in design of agents for
positron tomography. In other respects, studies with hyperpolarized
13C or 15N are quite different. For example, the half-lives (t1/2) of
tracers used typically in PET such as 11C or 18F (20 or 110 minutes,
respectively) are often much longer than polarized states achieved so
far, which often decay with relaxation times on the order of only 20
to 60 seconds. This problem is partially alleviated because, unlike
with nuclear medicine probes, there is no need to wait for clearance
of hyperpolarized probes before imaging; in fact, one images imme-
diately after the administration of the probe providing information
on uptake, biodistribution, and metabolism of the probe in a scan
time of a minute or less. This has several advantages such as the abil-
ity to image metabolism in a breath hold, observe fast metabolic
fluxes (i.e., the conversion of pyruvate to lactate by lactate dehydro-
genase [LDH]), and the ability to add a hyperpolarized metabolic
imaging scan to an MR clinical scan without significant time penalty.
Nonetheless, the short lifetimes significantly restrict the generality of
hyperpolarized MR for in vivo imaging.
PET nuclei have exact t1/2 values that are insensitive to their chem-
ical environment. T 1 relaxation times are dependent on the nucleus
but are also sensitive to a host of other factors including the applied
field, the location in a molecule, molecular structure and motion, and
the chemical environment. Despite this complexity, some generaliza-
tions can be made. Hydrogen nuclei, because of their large γ values,
interact more strongly with their surroundings and thus have relaxa-
tion times of a few seconds or less. Thus, whereas water protons have
been polarized using DNP and this offers the interesting possibility of
using water as a contrast agent, the short T 1 (2.7 seconds) is a limiting
factor for its use in vivo [101]. In many circumstances, the polariza-
tion of 13C and 15N molecular sites will persist for much longer. The
fundamental reason for the longer lifetimes of hyperpolarized 13C and
15N arises from their lower γ compared with that of protons. How-
ever, direct bonding to dipoles such as 1H, of course, reduces the T 1’s
of 13C and 15N significantly. Although some 15N-enriched hyper-
polarized probes have longer T 1’s compared with
13C probes, there
are significantly more carbon sites present in the metabolic probes
of interest. As a result, 15N use may be limited to a narrower range
of probes such as hyperpolarized 15N-choline [92].
Other nuclei that have been polarized using DNP include 6Li and
89Y. 89Y is a spin half-nucleus that is difficult to detect at thermal
polarization levels because of its small magnetic moment. However,
its long T1 (≫100 seconds) makes it attractive as a DNP probe. 89Y-
labeled complexes have been polarized using DNP to levels of up to
1527-fold above thermal equilibrium at 310 K [102]. 6Li also has a
long T 1 (∼120 seconds) and 6LiCl has been polarized using DNP
[95,102]; the decay of the hyperpolarized 6Li signal is extremely sen-
sitive to small quantities of MR contrast agents and can be used to
enhance the sensitivity of detection of these agents. Provided that suf-
ficient 6Li distribution and detection can be achieved, the decay of
the hyperpolarized 6Li signal can then be used as a sensitive probe to
detect trace quantities of MR relaxation agents.
Acquisition Techniques for Hyperpolarized
13C Imaging
Imaging the metabolic products of hyperpolarized 13C or other nuclei
places special demands on the MR scanner, the pulse sequences, and
data processing. The primary limitation arises from the T 1 relaxation
times of the label in the parent molecule and its metabolic product(s)
that causes the hyperpolarized signal to decay back to its thermal equi-
librium. The amount of detectable signal available for imaging will be
a function of the degree of polarization, the T 1 relaxation time, and
the concentration of the metabolite. As a rough estimate, the available
time for imaging with an initial signal enhancement of 10,000 is
probably five to nine times the T 1 relaxation time. Also, each RF ex-
citation, repeatedly applied during data acquisition, causes a loss of
hyperpolarized signal, and thus, acquisitions minimizing the number
of RF pulses are preferred. The optimum time window in which to
record a maximum signal arising from the metabolic products after
conversion will be a balance between systemic delivery of the hyper-
polarized compound and the rate of conversion to its downstream
metabolic products in the tissue/tumor region of interest.
Owing to the nonrenewable nature of the magnetization and fast
decay, signal sampling needs to minimize the acquisition time, min-
imize the number of excitation pulses, and maximize the retention of
polarized signal. How this is best achieved depends on the nature of the
measurement, on the T 1 relaxation time, and on the dynamics of the
process under observation. A variety of acquisition strategies have been
developed to maximize the signal-to-noise ratio (SNR) and resolution
while minimizing the number of excitations [103,104]. For slice or
coil-only localized spectroscopy, commonly a short repetition time
(compared withT 1) and a small flip angle pulse and acquire sequence
has been used [105,106].
If only a single resonance is to be measured, and any other spectral
lines can be excluded by for example, selective excitation, imaging
techniques developed for evaluation of hyperpolarized gases He
and Xe can be used [107]. Many studies have made use of small-
tip angle pulse sequences [80,105,108–112]. A variable flip angle
technique can maximize sampling of the available polarization while
ensuring that signal at each acquisition remains approximately con-
stant [113] rather than progressively declining as would be the case
with a constant flip angle acquisition. To optimize this approach, the
T 1 relaxation time(s) in vivo must be known, and the flip angle needs
to be accurately calibrated.
As the hyperpolarized magnetization decreases toward equilibrium,
the metabolic conversion of the substrate occurs rapidly, sometimes in
just a few seconds. Hence, for metabolic imaging, the desired infor-
mation lies in both the spectral domain, with the relative amplitudes
of the different chemical shift species, and the spatial and temporal
domains. This necessitates spectral encoding along with the rapid
acquisition of imaging data, which strongly influences the design of
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pulse sequences for this application. Several fast spectroscopic imaging
approaches that provide spatial and spectral information on the uptake
and metabolism of hyperpolarized probes have been used [113–115].
Single-slice two-dimensional spectroscopic imaging with elliptical cen-
tral k-space sampling has provided both spatial and spectral information
in a rapid acquisition for preclinical cardiac measurements [115]. A
three-dimensional volume sampling approach using phase encoding
in two spatial dimensions and an echo-planar readout gradient in the
third dimension has been widely used for 15-second 13C spectroscopic
imaging [113,114]. To improve acquisition time and efficiency for
practical clinical application, data acquisition accelerations achieved
by reducing the number of temporal samples and using advanced re-
construction methods to recover the missing information are being
explored. These include using a least squares approach and prior
knowledge about the spectral components [111], randomly distributed
samples, and a reconstruction based on L1 minimization (compressed
sensing) [103,116] and parallel signal reception [117].
Special excitation pulses have been used to reduce sampling of the
initially polarized substrate, thus leaving more polarization available
for detection as newly synthesized metabolites [118,119]. Pulses with
a spectral response consisting of multiple bands have been used
[120,121], with a smaller tip-angle band applied to the frequency
of the substrate and a larger tip-angle band applied to the frequencies
of the products. This approach has improved the SNR of the products
by preserving the polarization of the substrate and allowed serial spec-
troscopic imaging with a time resolution of 3 seconds to monitor the
temporal dynamics of 13C-pyruvate uptake and metabolism [120].
Physiology and Metabolism in Preclinical Models
A major challenge facing hyperpolarized MR is the relatively short
duration of polarization. This means that, to study metabolism,
the substrate must be rapidly transported through the bloodstream
to the tissue of interest, be rapidly taken up by the cell, and be rap-
idly metabolized. Furthermore (unlike PET tracers), the mass of the
substrate that must be injected is substantial and sufficient to alter
metabolic processes. If that substrate is to be used in the clinic then
it must be nontoxic at the relatively high concentrations. Alternative
substrates may be developed, but even if the substrates that have been
used successfully so far are the only ones to make it to the clinic, it is
already clear that these could provide unique and important informa-
tion on tumor grade, prognosis, and treatment response. In discuss-
ing the potential of hyperpolarized substrates for imaging cellular
metabolism in cancer and other diseases, perhaps the best approach
is to discuss the substrates or probes that have been successfully hyper-
polarized and to describe how they have been used in preclinical models
and their clinical potential.
Metabolism of Hyperpolarized Pyruvate
[1-13C]Pyruvate has been the most widely studied substrate to
date, reflecting its central role in cellular metabolism, the ease with
which it can be hyperpolarized, its relatively long T 1 relaxation time,
and its very rapid transport across the cell membrane and subsequent
metabolism. High solubility in water is also a factor because it means
that the concentration of the hyperpolarized material is still relatively
high after dissolution. Pyruvate, the end product of glycolysis, can be
reduced by the NADH produced in the pathway to generate lactate,
in the reaction catalyzed by the enzyme LDH. Alternatively, pyruvate
undergoes transamination with glutamate to form alanine, in the re-
action catalyzed by alanine transaminase (ALT). The reactions cata-
lyzed by both LDH and ALT are readily reversible in the cell and
therefore the polarized 13C label introduced in [1-13C]pyruvate can
effectively exchange with preexisting pools of lactate and alanine
[122]. A third reaction involves the irreversible decarboxylation of
[1-13C]pyruvate to hyperpolarized 13C-labeled carbon dioxide in
the reaction catalyzed by the mitochondrial enzyme, pyruvate dehy-
drogenase (PDH). The carbon dioxide released is subsequently inter-
converted with bicarbonate in the reaction catalyzed by carbonic
anhydrase. The reactions catalyzed by LDH and ALT have been ob-
served to be altered in cancer [110,123–126] as is the monocarbox-
ylate transporter that mediates pyruvate uptake and lactate export
[127]. All three reactions have been observed in normal and patho-
logic cardiac tissue [115,128–130].
MR observation of hyperpolarized products of pyruvate metabolism
can be performed with very high temporal resolution, up to one mea-
surement per second (Figure 1). The practicality of these kinetic mea-
surements opens the possibility that direct measurements of absolute
fluxes may be feasible in vivo at some point in the future. It is important
to emphasize that, as a consequence of the inherent chemical informa-
tion in the 13C NMR spectrum, the ability to detect metabolism of a
labeled molecule through a single enzyme-catalyzed reaction in vivo is
already a reality (Figure 1).
[1-13C]pyruvate: Applications to Cancer
In a murine lymphoma model, the LDH-catalyzed interconversion
of hyperpolarized label between pyruvate and lactate was shown to
decrease early after chemotherapy [124]. Transfer of this technique
to the clinic may allow an oncologist to determine whether a cancer
is responding to the treatment within hours of treatment. If the tumor
is not responding, a more effective treatment regimen could be initi-
ated; rapidly changing the patient to a more effective drug not only is
cost-effective but also can greatly improve morbidity and mortality
[71]. The decreased LDH-catalyzed flux in this study was explained
by a loss of the coenzyme NAD(H), decreases in tumor cellularity,
and reduced LDH concentrations. Another study compared the treat-
ment response detected with hyperpolarized pyruvate with that de-
tected from measurements of FDG uptake [131]. A decrease in
FDG uptake was found to precede the decrease in flux between py-
ruvate and lactate. However, by 24 hours after drug treatment, the
magnitude of both the decrease in FDG uptake and the decrease in
pyruvate to lactate flux was comparable.
Flux of hyperpolarized 13C label between pyruvate and lactate has
also been used as a marker of prostate cancer progression, with the levels
of hyperpolarized lactate increasing with increasing tumor grade in the
TRAMP model [123] (Figure 2). Determining tumor grade in the
clinic is normally limited by sampling problems during biopsy, but
transfer of this method to the clinic could allow noninvasive deter-
mination of the whole prostate. Another report has demonstrated sig-
nificantly higher hyperpolarized lactate production in two human
glioblastoma xenograft models, where the blood-brain barrier has been
disrupted, relative to normal brain, suggesting that hyperpolarized MR
metabolic imaging may be valuable for assessing prognosis and moni-
toring response to therapy for patients with brain tumors [125]. Tumor
oxygenation status is also a key determinant in both tumor growth and
response to therapeutic interventions, particularly radiation-based ther-
apies. Combined hyperpolarized MRI of [1-13C]pyruvate with electron
paramagnetic resonance imaging of the trityl radical, used in hyper-
polarization, has allowed the acquisition of images of hyperpolarized
lactate coregistered with PO2 maps in a murine tumor model [132].
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Numerous mechanism-based anticancer drugs that target oncogenic
signaling are in clinical trials. However, because such treatments can
lead to tumor stasis, it remains challenging to assess responses by tra-
ditional imaging methods. In a recent study, inhibition through the
phosphatidylinositol 3-kinase (PI3K/Akt/mTOR) pathway was shown
to correlate with a drop in hyperpolarized [1-13C]lactate levels in breast
cancer and glioblastoma cells and xenografts [126]. The reduced
appearance of lactate compared with pyruvate was attributed to a drop
in LDH expression as a result of reduced levels of the transcription
factor, hypoxia-inducible factor 1α, which regulates expression of
the LDH gene [126]. These findings highlight the value of this tech-
nique as a method to confirm drug delivery and drug target modula-
tion before, or in the absence of, apoptosis and a reduction in tumor
size. An alternative to the lactate-pyruvate ratio, which is critically de-
pendent on the timing of injection and subsequent data acquisition,
is to measure the lactate and pyruvate signals over time and fit these
to a kinetic model [124,126,133,134]. The fast spectroscopic imag-
ing techniques described can also provide spatially resolved dynamic
data of hyperpolarized pyruvate metabolism and spatially variable
uptake of pyruvate, and the pyruvate-to-lactate flux observed in trans-
genic prostate tumors was consistent with tumor cellularity and ne-
crosis [120].
Although the focus of this article is on the application of hyperpo-
larized [1-13C]pyruvate to cancer, preclinical studies have demon-
strated significant potential for studying both normal tissues and
other human diseases. Hyperpolarized [1-13C]pyruvate metabolism
has been measured both in vivo and in the isolated perfused rat
heart [115,128–130]. Metabolites identified include [1-13C]lactate,
[1-13C]alanine, and 13CO2. The latter was visualized through the
production of 13C-labeled bicarbonate (H13CO3
−) arising from the
reaction catalyzed by PDH [128] (Figure 1). Fasted animals showed
a reduction in hyperpolarized 13CO2 production compared with fed
controls, and a similar reduction was observed after the induction
of type 1 diabetes, where the decrease correlated with disease sever-
ity [106]. Total global ischemia in isolated perfused rat hearts re-
sulted in the production of [1-13C]lactate and [1-13C]alanine but
not H13CO3
− or 13CO2 [129]. When [2-
13C]pyruvate was used in-
stead of [1-13C]pyruvate [130], the 13C-label incorporated into citric
acid cycle intermediates rather than being released as 13CO2. In the
perfused rat heart, the conversion of pyruvate to lactate, acetyl-carnitine,
citrate, and glutamate was observed. The appearance of glutamate was
slightly later than the other metabolites demonstrating flux through
the citric acid cycle. After ischemia, citrate and glutamate decreased
and lactate increased.
Figure 1. (A) Diagram demonstrating the metabolism of [1-13C]pyruvate, which can be converted to [1-13C]lactate in a reaction catalyzed by
the enzyme LDH, [1-13C]alanine in a reaction catalyzed by ALT, and 13C-carbon dioxide in a reaction catalyzed by PDH). The carbon dioxide
released is subsequently interconverted with bicarbonate in a reaction catalyzed by carbonic anhydrase (CA). (B) The great strength of
hyperpolarized 13C NMR is the ability to measure not only the uptake of the labeled substrate but also its metabolic products. For example,
in the hyperpolarized 13C NMR spectrum of an isolated rat heart perfusedwith hyperpolarized [1-13C]pyruvate, metabolite resonances due to
13CO2, H
13CO3 [1-
13C]pyruvate, [1-13C]lactate, and [1-13C]alanine can be readily observed in a single acquisition. (C) Because of the dramatic
increase in sensitivity of hyperpolarized MR, hyperpolarized products of pyruvate metabolism can also be measured with a 1-second
temporal resolution and metabolic fluxes calculated from the kinetic information. Figure adapted from Merritt et al. [128].
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Detection of hyperpolarized pyruvate and its metabolic products has
also been demonstrated in liver [135], muscle, and kidney [105,110].
One study demonstrated significant differences in the lactate-to-alanine
ratio between the normal and fasted rat liver [135] and demonstrated a
highly elevated hyperpolarized lactate in liver cancer [116].
There has been some debate as to whether pyruvate crosses the
blood-brain barrier rapidly enough to allow imaging within the lifetime
of the polarization. A recent study demonstrated detectable cerebral
hyperpolarized [1-13C]pyruvate metabolism; however, the lipophilic
ethyl ester of pyruvate, ethyl pyruvate, was taken up and metabolized
to a higher degree [136]. This study demonstrated that high doses of
either hyperpolarized [1-13C]-pyruvate or ethylpyruvate may be viable
agents for brain imaging even in diseases that do not substantially affect
the blood-brain barrier, for example, infiltrating gliomas, Alzheimer
disease, nonenhancing multiple sclerosis, and acute stroke.
13C-Enriched Bicarbonate
Extracellular pH has been measured in tumors by injecting hyper-
polarizedH13CO3
− [137].Measurements of theH13CO3
−/13CO2 ratio
can be used to estimate the pH (pH = pK a + log10([H
13CO3
−] /
[13CO2]) (Figure 3). The technique is ratiometric, so it does not require
a measurement of absolute concentration, and the ratio changes by a
factor of 10 in the physiological pH range. The rapid interconversion
of H13CO3 and
13CO2, catalyzed by carbonic anhydrase, ensures that
the polarization decays at a similar rate in both species. pH images were
obtained bymeasuring theH13CO3/
13CO2 ratio in each imaging voxel,
which demonstrated that the extracellular pH in a lymphoma tumor
was more acidic than that in the surrounding tissue [137]. If this tech-
nique can be applied in the clinic, then it could be used as a generic
marker of disease given the wide range of pathologic states that are
associated with an acidic extracellular environment. Bicarbonate is
Figure 2. (A) Representative hematoxylin and eosin–stained pathologic sections (magnification, ×40) and hyperpolarized 13C spectra
from a normal mouse prostate, an early stage and late transgenic mouse prostate tumor (TRAMP), and a lymph node metastases. Below
the histologic sections are representative hyperpolarized 13C spectra acquired after injection of hyperpolarized [1-13C]pyruvate and nor-
malized to correct for differences in polarization. The normalized spectra exhibited a visually clear increase of hyperpolarized lactate and
hyperpolarized lactate-to-pyruvate ratio with progression from the normal to early and late-stage tumors and metastases. (B) Axial T2-
weighted 1H image depicting the primary tumor and lymph node metastasis from a TRAMP mouse with a late-stage primary tumor and
the overlay of hyperpolarized [1-13C]lactate image after the injection of 350 μl of hyperpolarized [1-13C]pyruvate. Hyperpolarized [1-13C]
lactate increased in going from normal to prostate cancer and with disease progression. (C) A box plot quantitatively summarizing the
peak area-to-noise ratios of the [1-13C]lactate-to-noise ratio for the four histologically defined groups. The lactate peak area SNR values
were statistically different (P < .05) for all four groups, except that early stage tumors were not significantly different from lymph node
metastases. In addition, there was minimal overlap between individual [1-13C]lactate-to-noise ratios between normal prostates and early
and late-stage tumors. Figure adapted from Albers et al. [123].
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abundant in tissue (∼25 mM) and is already infused into patients at
concentrations that would be needed for a hyperpolarized 13C imaging
measurement of tissue pH.
[1,4-13C2]fumarate
After intravenous injection of hyperpolarized [1,4-13C2]fumarate,
its metabolism to hyperpolarized [1,4-13C2]malate, catalyzed by the
enzyme fumarase, has been demonstrated in tumors and skeletal
muscle [138]. The signal from hyperpolarized malate increased sig-
nificantly in skeletal muscle after ischemia and reperfusion [138],
suggesting that it may be used as a positive contrast agent for iden-
tifying ischemic injury. The accumulation of malate was suggested to
be due to a block in the TCA cycle [138]. However, recent studies
in drug-treated tumors have demonstrated that the accumulation of
malate is due to cellular necrosis [139]. In viable cells, the transport
rate of fumarate into the mitochondria is too slow to enable the
observation of labeled malate within the lifetime of the polarization.
However, if this permeability barrier is removed, as it is in necrotic
cells, then fumarate conversion to malate can be observed. Fumarate
is potentially a useful agent for detecting treatment response in tumors
because the production of labeled malate would seem to be an un-
equivocal indicator of cell death.
[1-13C]lactate
[1-13C]Lactate has been hyperpolarized and investigated as an in vivo
metabolic imaging agent [140]. After intravenous injection in the
TRAMPmodel, only low levels of hyperpolarized [1-13C]pyruvate were
detected, and this presumably reflects the exchange of label into a rel-
atively small pool of tissue pyruvate. The hyperpolarized 13C label was
also diluted by flux into other metabolites, including [1-13C]alanine
and H13CO3
−. An important advantage of using lactate to introduce
the hyperpolarized 13C label is that the concentration of hyperpolar-
ized lactate in the blood after injection is similar to that seen in an
exercising animal; this differentiates it from hyperpolarized pyru-
vate, which is injected at a concentration that is much higher than is
found endogenously.
[5-13C]glutamine
Glutamine is important for tumor growth, and in many cell lines, its
utilization is positively correlated with cell proliferation. Imaging gluta-
mine metabolism could, therefore, be a marker of tumor growth and
division and is already safely administered to humans in the clinic. The
conversion of hyperpolarized [5-13C]glutamine to [5-13C]glutamate,
catalyzed by intramitochondrial glutaminase, has been demonstrated
in hepatocellular carcinoma cells in vitro [141]. The label in the C-5
position shows a larger chemical shift after conversion to glutamate
compared with the C-1 position, which aids detection of the metabo-
lite, although the T 1 is slightly shorter. The relatively low levels of
polarization obtained in this study precluded studies in vivo. However,
with higher levels of polarization, it may be possible to use this sub-
strate to assess the effects of tumor treatment with cytostatic drugs.
[1-13C]acetate
After injection of hyperpolarized [1-13C]acetate into mice, both
acetyl CoA and acetyl carnitine were observed in liver and heart,
although the acetyl carnitine signal from the heart was higher, demon-
strating an organ variation in the distribution of acetate metabolism
[142]. Ischemia in skeletal muscle was shown to result in a reduction
in acetyl-carnitine formation [142]. Carnitine can modulate fatty acid
and carbohydrate metabolism by modifying the intramitochondrial
acetyl-CoA/CoA ratio, and therefore, it is possible that this substrate
could be used to probe fatty acid metabolism.
[2-13C]-fructose
Owing to the limited lifetime of the hyperpolarized nucleus, with
signal decay dependent on T 1 relaxation, carboxylate carbons have
been the primary targets for development of hyperpolarized metabolic
probes. The use of these carbon nuclei makes it difficult to investigate
upstream glycolytic processes, which have been related to both cancer
metabolism as well as other metabolic abnormalities, such as fatty liver
disease and diabetes. Glucose carbons have short T 1’s (<1 second) and
therefore cannot be used as an in vivo hyperpolarized metabolic probe
of glycolysis. However, the pentose analog fructose can also enter gly-
colysis through its phosphorylation by hexokinase and yield com-
plementary information. The C2 of fructose is a hemiketal that has
a relatively longer relaxation time (∼16 seconds at 37°C) and high
solution state polarization (∼12%) [143]. Injection of hyperpolarized
[2-13C]-fructose into the TRAMP model demonstrated differences in
uptake and metabolism in regions of prostate cancer relative to sur-
rounding benign abdominal tissues [143].
Figure 3. (A) Transverse protonMR image of a mouse with a subcutaneously implanted EL4 tumor (outlined in red). (B) pHmap of the same
animal calculated from the ratio of the H13CO3 acquired 10 seconds after intravenous injection of 100 mM hyperpolarized H
13CO3
− and
assuming a pK a of 6.17 (pH = pK a + log ([HCO3] / [CO2]). Figure adapted from Gallagher et al. [137].
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[1-13C]succinate
Succinic acid has been hyperpolarized using PHIP [81]. Recently,
real-time metabolism of the molecule has been demonstrated in vivo
[144]. Furthermore, succinate can induce hypertension in animals
when administered intravenously [145]; it is unclear whether this effect
occurs in humans, but if it does, this may limit its clinical application.
[1-13C]-α-ketoisocaproate
α-Ketoisocaproate (KIC) is metabolized to leucine by the enzyme
branched-chain amino acid transferase (BCAT), which is found to
be upregulated in some tumors. BCAT is a putative marker for
metastasis and a target for the proto-oncogene c-myc. Injection of
hyperpolarized [1-13C]KIC into rodents have shown ample con-
version into leucine [146]. In a preclinical study, the SNR and con-
trast were compared between hyperpolarized [1-13C]pyruvate and
[1-13C]-KIC. Here, similar imaging abilities between the two sub-
strates were found. [1-13C]KIC showed a 2.5-times lower SNR com-
pared with [1-13C]pyruvate, whereas the contrast was 20% higher.
Very different fluxes through the BCAT-catalyzed reaction can be
detected for murine lymphoma (EL4) and rat mammary adeno-
carcioma (R3230AC) tumors in vivo [146]. KIC is suitable for the
profiling of tumors at the single gene level and introduced as a novel
imaging modality for tumors with high BCAT activity.
3,5-Difluorobenzoyl-L-glutamic Acid
Gene-directed enzyme prodrug therapy is a cancer treatment strat-
egy that aims to reduce systemic toxicity by systemically administering
a nontoxic prodrug that is converted to the toxic drug in the tumor
by a nonendogenous enzyme delivered by viral vectors only to tumor
cells. This complex strategy holds considerable promise for reducing
dose-limiting systemic toxicity but depends on the successful delivery
of the enzyme and the prodrug to the tumor. One enzyme system
of interest is the Carboxypeptidase G2 (CPG2) bacterial enzyme sys-
tem [147]. A hyperpolarized reporter probe has been developed, 3,5-
difluorobenzoyl-L-glutamic acid (3,5-DFBGlu), which is a substrate
for CPG2, and has been shown to report on CPGT enzyme activity
in vitro [97].
13C-choline and 15N-choline
Malignant transformation of cells is characterized by increased phos-
phocholine concentrations, and studies of both 1H and 31P MRS have
demonstrated elevated levels of this metabolite in many different forms
of tumor compared with the normal tissue [148]. 13C-labeled choline
can be polarized, but the carbon T1’s are short because of dipolar inter-
actions with directly bonded hydrogen atoms. 15N-labeled choline can
be hyperpolarized, and because it has a long T 1 (∼4 minutes), this
would make it suitable for imaging [92]. However, the small chemical
shift difference between the 15N resonances of choline and phospho-
choline (∼0.2 ppm) would make them difficult to differentiate in vivo
at clinical magnetic field strengths. This problem has been addressed by
transferring polarization to spin-coupled protons [94]. However, as yet,
there seems to be no evidence that the choline kinase–catalyzed phos-
phorylation of choline is sufficiently rapid, either in cells in vitro or in
tumors in vivo, to produce detectable levels of labeled phosphocholine
within the lifetime of the polarization.
Constraints on Translation to Clinical Application
A number of hurdles to the clinical translation of hyperpolarized meth-
ods must be overcome. These hurdles relate to technical and practical
issues associated with the components of the MR scanner and the
polarizer, concerns about safety of the hyperpolarized substrate, and
the challenges of developing well-validated, standardized protocols use-
ful across multiple centers. There are numerous other relevant issues
related to the commercialization of this technology, but these topics
are beyond the scope of this report.
MR Scanner Software and Hardware Constraints
Because the frequencies for 13C and 15N differ significantly from
that used for conventional 1H imaging, the radiofrequency hardware
including transmitters, receivers, filters, and amplifiers all need to be
tuned to these specific frequencies. Also, the spatial localization neces-
sary for 13C and 15N MRS and MRI inherently is more demanding
than conventional 1H MR. This is because of the significantly lower
γ for these nuclei, therefore requiring ∼16× and 100× more gradient
power to achieve the same spatial resolution for 13C and 15N, respec-
tively. Although clinical MR scanners are typically proton-only sys-
tems, MR manufacturers have provided multinuclear capabilities for
many years and can certainly overcome the previously mentioned con-
straints. Decoupling is also not essential for hyperpolarization applica-
tions because it provides only minor signal gains compared with that
of hyperpolarization itself, although it will provide a sharpening of
hyperpolarized resonances that are coupled to protons [149] with the
challenge of remaining within SAR limitations. New pulse sequence
developments are required because the properties of hyperpolarized
agents are inherently different from endogeneous nonhyperpolarized
molecules as described in the Physiology and Metabolism in Preclinical
Models section. However, most of the fast 13C MRSI pulse sequences
that have been developed for preclinical studies are directly translatable
to clinical MR scanners and patient studies. Finally, the design and
construction of new specialized radiofrequency coils for 13C and 1H
excitation and reception suitable for future human studies is required
(Figure 4). Radiofrequency coils for 13C (and other nuclei) have his-
torically been custom made by smaller companies and laboratory built
but would need to be provided for hyperpolarized clinical studies by,
or in collaboration with, the MR manufacturer.
Generating Hyperpolarized Material with a Sufficiently
Long T1
A critical need is developing polarizer equipment that can con-
veniently generate a hyperpolarized sample. The requirements for this
equipment can be summarized as follows. The polarized product must
be sterile and at an acceptable temperature and pH. The material must
be free (and proven to be free) from any radical used during the polar-
ization process. The product must be delivered to the subject with a
delay of less than 20 seconds to limit signal lost due to relaxation. Such
an instrument should provide multiple samples in a timely manner
with high polarization and reproducibility. For clinical applications,
polarizers must be designed to allow siting close to the clinical MR scan-
ner for facilitated delivery of the hyperpolarized probe.
Although having a sufficiently long T 1 is a significant challenge for
the clinical translation of hyperpolarized MR, it is already clear that the
hyperpolarized probes that have been used successfully so far in preclin-
ical studies can provide unique and important clinical information with
regard to disease diagnosis, prognosis, and treatment response (Con-
clusions and Recommendations section). Hyperpolarized probes used
to date have taken advantage of the longer T 1’s of low γ nuclei such
as 13C and 15N and by placing the 13C and 15N label in a chemical
environment without directly bonded protons. Replacing protons (1H)
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with deuterons (2H) in a molecule can also prolong 13C T 1’s, but the
magnitude of this effect depends on the molecule and the site of the
13C/15N label. Longer-lived hyperpolarized probes can also be created
by exploiting molecular symmetry to store spin populations in states
(singlet-state) that are inherently isolated and have dramatically longer
T 1 relaxation times [87–90,150,151]. Other approaches for lengthen-
ing hyperpolarized probe T 1’s are also being investigated. One such
approach uses hyperpolarized 13C or 15N sites to store hyperpolari-
zation, whereas the MR signal is detected through polarization trans-
fer (e.g., insensitive nuclear enhancement by polarization transfer) to
J-coupled protons [83,94]. Another approach uses a reactive molecule
that hyperpolarizes well and has a relatively long T 1 to chemically
“tag” biomolecules of interest with the longer-lived hyperpolarized label
[152]. However, the fundamental upper limits of achievable T 1 times
in vivo using these approaches are an area of active research.
For patient studies, the probe needs to have a sufficient T 1 relaxation
time to overcome the longer blood circulation time of patients relative
to preclinical animal models. On the basis of preclinical large animal
studies of hyperpolarized [1-13C]pyruvate, its in vivo T 1 relaxation time
was sufficiently long to be delivered to and metabolized in the canine
prostate [153] (Figure 4). The delivery time of gadolinium-based con-
trast agents to the human prostate (enhancement onset ≈ 15 seconds
after the start of injection) suggests that this will also be true of hyper-
polarized [1-13C]pyruvate studies in patients [154]. However, such T 1
relaxation time assessments will need to be performed on all new
hyperpolarized probes.
Safety of the Agent
In many cases, the molecules currently under study—pyruvate,
bicarbonate, lactate, and others—are products of normal intermediary
metabolism and are normally present in vivo. Hence, the molecules
themselves are inherently safe, and there is an enormous knowledge
base about their metabolism as well as their effects in mammals includ-
ing humans. However, current hyperpolarization methods require that
a significant amount of hyperpolarized material must be delivered.
Consequently, unlike PET, it is possible that the hyperpolarized sub-
strate itself will influence metabolic processes. The potential physiologi-
cal consequences of the hyperpolarized substrate must also be carefully
evaluated, and this evaluation is an important focus of current research.
Hyperpolarized [1-13C]pyruvate, for example, is being developed for
clinical studies of prostate cancer. In preparation for human studies,
initial dose-escalation safety and tolerability studies were performed
in rats, in anesthetized and conscious dogs (Figure 4), and nonhy-
perpolarized [1-13C]pyruvate in human volunteers [155]. To date, no
Figure 4. Prototype polarizer (top left) has been installed in a clean room adjacent to a 3-T clinical MR scanner in preparation for a phase 1
clinical trial of [1-13C]pyruvate in prostate cancer patients. The 13C/1H coil designs shown (bottom left) are those that will be used in the
patient studies. These coils have been tested in canine studies and provided the 13C MRSI data shown on the right. On the top right is a
representative canine prostate 13C MRSI array obtained after injection of hyperpolarized [1-13C]pyruvate dose volume of 1.4 ml/kg of body
weight, a dose that was determined to be safe in healthy human volunteer studies. The corresponding [1-13C]pyruvate and [1-13C]lactate
images overlaid on a axial T2-weighted image of the canine prostate is shown on the bottom right. The
13C MRSI data were collected in
15 seconds at a spatial resolution of 0.125 cm3 demonstrating high levels of [1-13C]pyruvate (SNR, ≥200) and lower [1-13C]lactate levels
consistent with normal canine prostate tissue metabolism (right). These preliminary MR metabolic imaging studies demonstrated that the
T 1 of hyperpolarized [1-
13C]pyruvate was sufficient to allow delivery to the prostate and metabolism in a large animal. In addition, there
was sufficient sensitivity to detect metabolism throughout the prostate at a much greater spatial and temporal resolution than previously
possible with other MR metabolic imaging techniques. Figure adapted from Nelson et al. [153].
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significant adverse effects have been observed, and hyperpolarized
[1-13C]pyruvate has Investigational New Drug approval for initial use
in prostate cancer patients, with a phase 1 clinical trial poised to begin.
Standardized Protocols
The translation of high-end imaging techniques into clinical practice
requires the development and optimization of imaging protocols, estab-
lishing quality assurance and standardization protocols and sufficient
patient studies necessary to establish the best clinical applications of
the technology [156]. In many respects, hyperpolarized science will
need to repeat many of the evaluation protocols that were developed
for understanding the relative roles of other imaging modalities. The
development and validation of the new and emerging imaging technol-
ogies for clinical research and practice, such as hyperpolarized imaging
methods, pose new problems that require broad expertise and resources
to solve. The translation process requires not only basic technique de-
velopment and integration on commercial platforms but also patient
validation studies necessary to adequately demonstrate the clinical value
of the new imaging technique and to establish robust acquisition and
analysis protocols. The clinical translation of hyperpolarized imaging
techniques could therefore benefit greatly from the help of groups such
as the National Institutes of Health (NIH) Translational Research
Working Group whose mandate is to help integrate the complementary
skills and expertise of both academic institutions and industry to jointly
pursue specific early stage product development opportunities [156].
Conclusions and Recommendations
For many years, it has been known that tumor metabolism differs
dramatically from normal tissues in many respects. The advent of
molecular methods has illuminated the links between oncogenes and
metabolic activity, and the recently introduced concept that some can-
cers arise as a consequence of abnormal metabolism has generated
intense interest. Although the detection of hyperpolarized nuclei in
biologic systems is relatively recent, it is already established that MRI
of hyperpolarized nuclei, particularly 13C, provides information that
is intrinsically not available using current molecular imaging meth-
ods. This information—the detection of metabolism in individual
enzyme-catalyzed reactions—offers a fundamentally new approach to
imaging and understanding cancer biology in both primary and meta-
static lesions. Furthermore, despite the relatively limited data available
from in vivo studies, there are no obvious issues that prohibit transla-
tion to humans. In view of this opportunity for improved imaging and
the need for improved imaging of primary and metastatic cancers, we
have a number of recommendations.
First, hyperpolarized MR studies would greatly benefit from further
work focused on better understanding correlations between enzyme-
catalyzed reactions and malignancy. Many fundamental questions are
involved: What are the most informative reactions or pathways? Which
reactions are most sensitive to therapy? Which reactions correlate with
prognosis? This effort could but does not necessarily involve hyper-
polarization in the early stages; a number of methods are suitable for
probing metabolism in cells and animal models. This effort, of course,
could immediately involve integration of hyperpolarization techniques
with standard methods for measuring metabolic fluxes in cell and
animal models. Numerous aspects of cancer biology—early detection
of cancers and diseases, characterization of tumor microenvironments,
prediction of disease severity and cancer outcome, evaluation of thera-
peutic responses, and others—could be the targets of this effort.
Second, technology should be developed for efficient, convenient,
and reproducible and cost-effective production of large quantities of
highly polarized materials. Methods to store polarizations for prolonged
periods should be investigated.
Third, there is a need for development of new agents enriched with
either 13C or 15N that combine two features: long T 1 of the hyper-
polarized nucleus and rapid entry into meaningful biochemical path-
ways. This effort will require strong collaboration between synthetic
chemists and biochemists with expertise in intermediary metabolism.
Fourth, at this early stage in its development, the MR community
has the opportunity to develop coherent strategies to standardize and
harmonize methods for hyperpolarized MR data acquisition and dis-
play. Common protocols for quality assurance, calibration, software
for data analysis, and others are all important objectives. Ideally, these
methods are independent of the imaging platform.
Fifth, the rapid development of hyperpolarized MR methods will
require involvement from multiple sites and multiple research teams.
The opportunity exists to foster academic and industry collaborations
through polarizers and large-animal systems at multiple research sites.
Finally, it is important for imaging researchers to develop a consensus
on how to validate these emerging HP methods to help accelerate clini-
cal research.
This report generated from a wide range of researchers and imaging
physicians is a reflection of a strong interest by the research community
in moving this important new imaging method forward to address the
cancer problem and other diseases. It is difficult to imagine the rela-
tively primitive state of clinical imaging, less than 40 years ago, when
a “staging laparotomy” was a state-of-the-art diagnostic method prac-
ticed at the most advanced oncology centers. Each technology that
we now take for granted required strong collaborations across multiple
disciplines and the investment of significant resources. Progress in basic
physics and chemistry again presents the medical and scientific com-
munity with an opportunity to fundamentally improve clinical imaging
of cancer.
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